SCHEMBL2076848

SCHEMBL2076848

CS(=O)(=O)OCCOCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
NAAA Q02083 1/20 0.44
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
AR P10275 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
MMP9 P14780 1/20 0.40
ALOX15 P16050 1/20 0.40
AGTR1 P30556 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10316643 0.98 TSHR (0.48) TSHRCA1CA2CA9NAAA
SCHEMBL12013298 0.98 TSHR (0.48) TSHRCA1CA2CA9NAAA
SCHEMBL6379981 0.98 TSHR (0.48) TSHRCA1CA2CA9NAAA
SCHEMBL30388469 0.98 TSHR (0.48) TSHRCA1CA2CA9NAAA
SCHEMBL25622617 0.98 TSHR (0.48) TSHRCA1CA2CA9NAAA
SCHEMBL24773083 0.93 TSHR (0.44) TSHRCA1CA2CA9NAAA
SCHEMBL27032384 0.93 TSHR (0.44) TSHRCA1CA2CA9NAAA
SCHEMBL29198550 0.93 L3MBTL1 (0.47) TSHRCA1CA2CA9NAAA
SCHEMBL2568738 0.92 L3MBTL1 (0.49) TSHRCA1CA2CA9NAAA
SCHEMBL2078239 0.89 ALDH1A1 (0.52) TSHRCA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-8245617-A None JP disclosed
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 US disclosed
WO-2025126115-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE BEIGENE SWITZERLAND GMBH (CH) 2025-06-19 WO disclosed
US-12029708-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2024-07-09 US disclosed
US-11986531-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2024-05-21 US disclosed
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 US disclosed
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 US disclosed
US-20230192952-A1 BRANCHED TYPE HETERO MONODISPERSED POLYETHYLENE GLYCOL, PRODUCTION METHOD THEREOF, AND CONJUGATE THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2023-06-22 US disclosed
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ONCOLYS BIOPHARMA, INC. (JP) 2023-06-22 US disclosed
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ONCOLYS BIOPHARMA, INC. (JP) 2023-06-22 US disclosed
EP-0544412-B1 Rhenium and technetium complexes containing a hypoxia-localizing moiety BRACCO INT BV (NL) 1997-07-23 EP disclosed
JP-H08245617-A COMPOUND OF LIGAND HAVING SELECTIVITY AGAINST SODIUM ION AND ION SENSOR SUZUKI KOJI 1996-09-24 JP disclosed
WO-1995022330-A1 ANTIVIRAL AGENTS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1995-08-24 WO disclosed
EP-0394440-B1 PHENYLCARBOXYLIC ACID DERIVATIVES OTSUKA PHARMA CO LTD (JP) 1994-05-11 EP disclosed
EP-0544412-A2 Rhenium and technetium complexes containing a hypoxia-localizing moiety BRACCO INTERNATIONAL B.V. (NL) 1993-06-02 EP disclosed
US-4999378-A Antilipemic, anticholesterol, antidiabetic, treatment of atherosclerosis and obesity OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1991-03-12 US disclosed
EP-0394440-A1 PHENYLCARBOXYLIC ACID DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-10-31 EP disclosed
US-4937268-A TREATMENT OF ASTHMA, CHRONIC BRONCHITIS GLAXO GROUP LIMITED (GB) 1990-06-26 US disclosed
EP-0286242-A2 Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them GLAXO GROUP LIMITED (GB) 1988-10-12 EP disclosed
US-4727067-A TREATMENT OF ANGINA PECTORIS, CARDIAC ARRHYTHMIA, HYPERTENSION, DEPRESSION CIBA-GEIGY CORPORATION (US) 1988-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029708-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER TSHR 2964/4885CA1 4852/4885CA2 3650/4885
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, SARS1 TSHR 3786/4885CA1 4223/4885CA2 475/4885
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER TSHR 2971/4885CA1 4856/4885CA2 3656/4885
US-20230192952-A1 BRANCHED TYPE HETERO MONODISPERSED POLYETHYLENE GLYCOL, PRODUCTION METHOD THEREOF, AND CONJUGATE THEREOF ADCY7, BDKRB2, ADCY3 TSHR 1888/4885CA1 1464/4885CA2 2114/4885
US-11986531-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL TSHR 2304/4885CA1 3341/4885CA2 4045/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 TSHR 1899/4885CA1 3147/4885CA2 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.